tiprankstipranks
Metagenomi, Inc. (MGX)
NASDAQ:MGX
US Market

Metagenomi, Inc. (MGX) Stock Price & Analysis

27 Followers

MGX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$5.50 - $12.74
Previous Close$6.38
Volume24.96K
Average Volume (3M)116.42K
Market Cap
$239.02M
Enterprise Value-$5.70M
Total Cash (Recent Filing)$292.93M
Total Debt (Recent Filing)$48.21M
Price to Earnings (P/E)
Beta4.56
May 14, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding37,464,201
10 Day Avg. Volume41,535
30 Day Avg. Volume116,425
Standard Deviation0.16
R-Squared1.00
Alpha-0.21
Financial Highlights & Ratios
Price to Book (P/B)-2.01
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.33
Enterprise Value/EbitdaN/A
Forecast
Price Target Upside176.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say
Financial HealthMetagenomi's robust financial standing with approximately $327M in cash reserves provides a foundation for sustained operations and growth into 2027.
Product DevelopmentMetagenomi's CAST system is capable of large scale DNA-templated integrations, setting a strong position in the competitive gene editing market.
Upcoming MilestonesAn anticipated update on Metagenomi's Hemophilia A program may serve as a pivotal derisking event, potentially boosting investor confidence in the company's gene editing platform.
Bears Say
Financial PerformanceMetagenomi reported a 2023 net loss of $68.3 million, highlighting ongoing financial challenges.
Partnership ConcernsThe PH1 program with Moderna was not a commercially viable opportunity, casting doubts on the value of the partnership.
Stock Valuation RisksAnalyst sets a bearish $7 price target on MGX stock due to mixed non-human primate data, slow progression to clinical trials, and a recent setback in its platform technology.
---

Financials

Annual

Ownership Overview

33.30%0.85%26.24%39.61%
33.30% Insiders
26.24% Other Institutional Investors
39.61% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

MGX FAQ

What was Metagenomi, Inc.’s price range in the past 12 months?
Metagenomi, Inc. lowest stock price was $5.50 and its highest was $12.74 in the past 12 months.
    What is Metagenomi, Inc.’s market cap?
    Currently, no data Available
    When is Metagenomi, Inc.’s upcoming earnings report date?
    Metagenomi, Inc.’s upcoming earnings report date is May 14, 2024 which is 19 days ago.
      How were Metagenomi, Inc.’s earnings last quarter?
      Metagenomi, Inc. released its earnings results on Mar 27, 2024. The company reported -$5.667 earnings per share for the quarter, beating the consensus estimate of -$5.67 by $0.003.
        Is Metagenomi, Inc. overvalued?
        According to Wall Street analysts Metagenomi, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Metagenomi, Inc. pay dividends?
          Metagenomi, Inc. does not currently pay dividends.
          What is Metagenomi, Inc.’s EPS estimate?
          Metagenomi, Inc.’s EPS estimate is -$0.84.
            How many shares outstanding does Metagenomi, Inc. have?
            Metagenomi, Inc. has 37,464,203 shares outstanding.
              What happened to Metagenomi, Inc.’s price movement after its last earnings report?
              Metagenomi, Inc. reported an EPS of -$5.667 in its last earnings report, beating expectations of -$5.67. Following the earnings report the stock price went up 3.976%.
                Which hedge fund is a major shareholder of Metagenomi, Inc.?
                Among the largest hedge funds holding Metagenomi, Inc.’s share is RA Capital Management. It holds Metagenomi, Inc.’s shares valued at 18M.
                  ---

                  Company Description

                  Metagenomi, Inc.

                  At Metageno­mi, we are cre­at­ing poten­tial­ly cura­tive ther­a­peu­tics using our metage­­nomics-pow­ered genome edit­ing toolbox.We believe tools with capa­bil­i­ties that go beyond the cur­rent tech­nol­o­gy land­scape will be required in order to reach the full ther­a­peu­tic poten­tial of genome edit­ing. By har­ness­ing the pow­er of metage­nomics, the study of genomes recov­ered from uncul­ti­vat­ed organ­isms in the nat­ur­al envi­ron­ment, we are dis­cov­er­ing and devel­op­ing asuite of nov­el genome edit­ing tools with the poten­tial to make any desired ther­a­peu­tic gene edit, any­where in the human genome.
                  ---

                  MGX Stock 12 Month Forecast

                  Average Price Target

                  $17.67
                  ▲(176.96% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","26":"$26","10.25":"$10.25","15.5":"$15.5","20.75":"$20.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$17.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,10.25,15.5,20.75,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2023","6":"Dec<br/>2023","9":"Mar<br/>2024","12":"May<br/>2024","25":"May<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.32,7.756923076923077,9.193846153846154,10.630769230769232,12.067692307692308,13.504615384615384,14.941538461538462,16.37846153846154,17.815384615384616,19.252307692307692,20.689230769230768,22.126153846153848,23.563076923076924,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.32,7.193076923076924,8.066153846153847,8.93923076923077,9.812307692307693,10.685384615384617,11.55846153846154,12.431538461538462,13.304615384615385,14.17769230769231,15.050769230769232,15.923846153846155,16.79692307692308,{"y":17.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.32,6.295384615384616,6.270769230769231,6.246153846153846,6.2215384615384615,6.196923076923077,6.172307692307692,6.147692307692308,6.1230769230769235,6.098461538461539,6.073846153846154,6.049230769230769,6.024615384615385,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.27,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":11.27,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":11.27,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":11.27,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":11.27,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":11.27,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":11.27,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":11.27,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":11.27,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":12,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":11.78,"date":1709856000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.83,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.32,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

                  Best Analysts Covering MGX

                  1 Year
                  Yanan ZhuWells Fargo
                  1 Year Success Rate
                  0/2 ratings generated profit
                  0%
                  1 Year Average Return
                  -23.75%
                  reiterated a buy rating 19 days ago
                  Copying Yanan Zhu's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -23.75% per trade.
                  Popular Stocks
                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis